


 Cite this: *RSC Adv.*, 2024, **14**, 2905

Benzothiazole DNA gyrase inhibitors and their conjugates with siderophore mimics: design, synthesis and evaluation†

Martina Durcik,^a Cristina D. Cruz,^b Mariano Andrea Scorciapino,^{ID c} Janez Ilaš,^{ID a} Päivi Tammela,^{ID b} Matteo Ceccarelli,^{ID d} Lucija Peterlin Mašič^a and Tihomir Tomašić^{ID *a}

Benzothiazole-based bacterial DNA gyrase and topoisomerase IV inhibitors are promising new antibacterial agents with potent activity against Gram-positive and Gram-negative bacterial strains. The aim of this study was to improve the uptake of these inhibitors into the cytoplasm of Gram-negative bacteria by conjugating them to the small siderophore mimics. The best conjugate **18b** displayed potent *Escherichia coli* DNA gyrase and topoisomerase IV inhibition. The interaction analysis of molecular dynamics simulation trajectory showed the important contribution of the siderophore mimic moiety to binding affinity. By NMR spectroscopy, we demonstrated that the hydroxypyridinone moiety alone was responsible for the chelation of iron(III). Moreover, **18b** showed an enhancement of antibacterial activity against *E. coli* JW5503 in an iron-depleted medium, clearly indicating an increased uptake of **18b** in this bacterial strain.

Received 6th December 2023

Accepted 11th January 2024

DOI: 10.1039/d3ra08337c

rsc.li/rsc-advances

Introduction

Antimicrobial resistance (AMR) is one of the greatest challenges of modern medicine, and the number of deaths attributable to AMR is steadily increasing.¹ Due to the continued emergence of resistant bacteria, particularly in the ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter species*) group of pathogens, the development of novel therapeutic agents that act *via* novel mechanisms of action is of utmost importance.² DNA gyrase and topoisomerase IV are validated targets for antibacterial drug discovery. These bacterial type IIA topoisomerases are responsible for maintaining the correct topology of the DNA molecule during its replication, transcription, decatenation, and repair.^{3,4} The DNA gyrase consists of two catalytic GyrA subunits and two GyrB subunits with ATPase activity, whereas the topoisomerase IV consists of two catalytic ParC subunits and two ATP-binding ParE subunits.

Both enzymes exert their enzymatic activity as functional heterotetramers in the form A₂B₂.^{3,5} The clinically used fluoroquinolones⁶ and spiropyrimidinetriones (e.g. zolifludacin),⁷ which are in clinical development, bind in complexes bordered by DNA, GyrA (ParC) and GyrB (ParE), whereas gepotidacin, a member of the NBTI class,⁸ binds to DNA and GyrA (ParC). The GyrB and ParE subunits, which are critical for providing energy for enzymatic reactions through ATP hydrolysis, are inhibited by the clinically used novobiocin, which has been withdrawn from therapy due to side effects and development of resistance.⁹ Fobrepodacin (SPR720) and DS-2969b are GyrB/ParE inhibitors currently in clinical development for the treatment of non-tuberculous mycobacterial infections¹⁰ and against *Clostridium difficile* infections,¹¹ respectively.

Recently, we developed the benzothiazole class of ATP-competitive dual DNA gyrase and topoisomerase IV inhibitors that exhibit potent antibacterial activity against Gram-positive (G+) and Gram-negative (G-) problematic ESKAPE pathogens.¹²⁻¹⁵ These resistant G+ and G- bacteria are known to be responsible for the majority of nosocomial infections. Because they are highly resistant to clinically available antibiotics,^{16,17} most of these bacterial strains are also on the priority lists of WHO and CDC.^{18,19} The problem is challenging especially for G- species, which are protected by the additional outer membrane (OM), a real physical barrier for molecules to reach the periplasm.²⁰ Although porins expressed in the OM constitute the main path for molecules to penetrate, their permeability might not be sufficient to have a minimal internal accumulation.²¹ Thus other strategies are required, such as the exploitation of active siderophore transporters.²²

^aUniversity of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. E-mail: tihomir.tomasic@ffa.uni-lj.si

^bDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P. O. Box 56 (Viikinkaarila 5 E), FI-00014 Helsinki, Finland

^cDepartment of Chemical and Geological Sciences, University of Cagliari, Cittadella Universitaria di Monserrato - S. P. 8 km 0.700, 09042 - Monserrato (CA), Italy

^dDepartment of Physics and IOM/CNR, Sezione di Cagliari, University of Cagliari, Cittadella Universitaria di Monserrato - S. P. 8 km 0700, 09042 - Monserrato (CA), Italy

† Electronic supplementary information (ESI) available: Representative analytical data (NMR spectra, HRMS spectra, HPLC chromatograms). See DOI: <https://doi.org/10.1039/d3ra08337c>



We have previously also designed and evaluated conjugates of the (*S*)-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine-based GyrB/ParE inhibitors^{23,24} with small siderophore mimics²⁵ as a strategy to improve low cell-wall penetration of G $-$ bacteria.^{26–28} Siderophores, which are usually catechol or hydroxamic acid derivatives, are secondary microbial metabolites synthesized to sequester iron(III).²⁹ Bacteria synthesize siderophores and release them into the host environment to take up very limited amounts of freely available iron during infection.³⁰ Subsequently, the siderophore in complex with iron(III) is transported through the bacterial cell wall by iron uptake proteins. Conjugation of the antibacterial agent with the siderophore or siderophore mimic (*e.g.*, catechol, hydroxypyranone, hydroxypyridone or dihydroxypyridone) can be used to hijack the bacterial iron-uptake machinery to increase the periplasmic or cytoplasmic concentration of the antibiotic and thus, enhance its antibacterial activity.^{22,31–33} This concept was also clinically validated, when in November 2019 the FDA approved cefiderocol, a siderophore cephalosporin antibiotic, for the treatment of complicated urinary tract infections. Cefiderocol is also being studied in phase 3 clinical trials for the treatment of nosocomial pneumonia and infections caused by carbapenem-resistant G $-$ bacteria.^{34,35}

In the present work, we conjugated our potent, dual-targeting benzothiazole-based GyrB/ParE inhibitors with small siderophore mimics and investigated their DNA gyrase and topoisomerase IV inhibition, antibacterial activity, and binding of iron(III) by NMR spectroscopy. In addition, the binding mode of the most potent conjugate was evaluated by molecular dynamics simulation and analysis of the interactions in the ATP-binding site of *E. coli* GyrB.

Results and discussion

Design and synthesis

The design of new DNA gyrase inhibitor-siderophore mimic conjugates started from our potent GyrB/ParE inhibitors **A** and **B** (Table 1) that exhibited antibacterial activity against G $+$ and G $-$ ESKAPE pathogens, limited potential for resistance development and efficacy in *in vivo* infection models.^{13,14,36,37} The co-crystal structures of benzothiazole GyrB inhibitors in complex with *S. aureus* GyrB showed that the pyrrolamide moiety forms two hydrogen bonds with Asp81 (*S. aureus* GyrB numbering) and crystal water molecule as well as an extensive network of hydrophobic contacts. The benzothiazole core is engaged in the formation of cation–π interaction with Arg84 and substitution at position 4 allows for improving the physico-chemical properties and binding affinity by formation of additional interactions in the lipophilic floor of the binding site. Moreover, the carboxylate at position 6 forms a strong salt bridge with Arg144 (Fig. 1).^{13,14,36,37}

In the design of conjugates with siderophore mimics, we considered two different approaches. In the first design strategy, the 6-carboxylic acid was reacted with the 2-(aminomethyl)-5-hydroxy-4H-pyran-4-one or 2-(aminomethyl)-5-hydroxypyridin-4(1H)-one to form the amide derivatives **10** and **12**. In the second strategy, a siderophore mimic was

incorporated into position 4 of the benzothiazole core to obtain compounds **18a** and **18b**. In both approaches we anticipated that the siderophore mimic would form attractive interactions within the GyrB/ParE ATP-binding site and therefore, its cleavage from the inhibitor would not be a prerequisite for enzyme inhibition, as previously reported for some GyrA inhibitors conjugated to siderophores.^{38–40} We used 4,5-dibromo- or 3,4-dichloro-5-methylpyrrole moiety as both form similar interaction network in the GyrB binding site. The advantage of our approach is also that the resulting conjugates have molecular weight around 500 and therefore, better drug-like properties than previously reported ciprofloxacin-siderophore conjugates with cleavable and non-cleavable linkers.

The synthesis of the siderophore mimic building blocks **4** and **6** started from kojic acid (**1**) (Scheme 1).⁴¹ The hydroxyl group at position 3 of **1** was selectively protected using the 4-methoxybenzyl (PMB) chloride in the presence of potassium carbonate in *N,N*-dimethylformamide (DMF) to obtain compound **2**. Hydroxyl group of the hydroxymethylene group at position 5 of compound **2** was then activated with methanesulfonyl chloride to mesylate **3**, which was converted in nucleophilic substitution with the sodium bromide to bromide **4** or with the sodium azide to azide **5**. The latter was converted to amine **6** using Staudinger reaction conditions.

DNA gyrase inhibitor-siderophore mimic conjugates were first prepared by attaching the siderophore mimic to the carboxylic acid group at position 6 on the benzothiazole ring (Scheme 2). Firstly, EDC/HOBt-promoted amide coupling between the 2-aminobenzothiazole-6-carboxylic acid (**7**) and siderophore mimic building block **6** gave compound **8**, which was in the next step coupled with the 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one in the presence of sodium carbonate as a base in DMF to yield pyrrolamide **9**. Final conjugate **10** was prepared by the removal of the 4-methoxybenzyl protecting group of **9** using HCl in acetic acid. 4H-Pyran-4-one derivative **9** was also converted to the pyridin-4(1H)-one derivative **11** by refluxing **9** in aqueous ammonia solution. DNA gyrase-siderophore conjugate **12** was finally prepared by deprotection of the 4-methoxybenzyl group of **11** under acidolysis conditions.

In addition to the attachment of siderophore mimics to position 6 of the benzothiazole, we also considered introducing such structural elements to position 4 of this scaffold (Scheme 3). The synthesis of final compounds **18a** and **18b** started from methyl 2-amino-4-hydroxybenzothiazol-6-carboxylate (**13**)⁴² that was alkylated with the building block **4** under basic conditions to obtain compound **14**. Pyrrolamides **15a** and **15b** were obtained by reacting amine **14** with the 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one or 2,2,2-trichloro-1-(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)ethan-1-one, respectively, in the presence of sodium carbonate in DMF. 4H-Pyran-4-one derivatives **15a** and **15b** were refluxed in ammonium hydroxide to obtain pyridin-4(1H)-one derivatives **16a** and **16b**. To prepare final conjugates **18a** and **18b** the order of removal of protecting groups was important. First, methyl ester of **16a** and **16b** was cleaved using alkaline hydrolysis to get **17a** and **17b**, followed by acidolysis to yield final products **18a** and **18b**.



Table 1 *Escherichia coli* DNA gyrase and topoisomerase IV inhibition by compounds **10**, **12**, **18a**, and **18b**

ID	Structure	IC ₅₀ [nM]	
		<i>E. coli</i> DNA gyrase	<i>E. coli</i> topoisomerase IV
A		13 ± 0	500 ± 280
B		<10	350 ± 50
10		1420 ± 180	>10 000
12		1700 ± 360	>10 000
18a		12 ± 5	1280 ± 820
18b		22 ± 6	430 ± 20





Fig. 1 The binding mode of inhibitor B (in grey sticks) in complex with *Staphylococcus aureus* GyrB24 (in blue cartoon; PDB entry: 6TCK). For clarity, only amino acid residues forming hydrogen bonds or cation–π interaction are shown as grey sticks. Water molecule is presented as a red sphere. Hydrogen bonds are shown as green (hydrogen bond donor) and red (hydrogen bond acceptor) arrows.

In vitro enzyme inhibition

All final compounds were first tested for their inhibitory activity in the *E. coli* DNA gyrase supercoiling assay and the *E. coli* topoisomerase IV relaxation assay (Table 1). The enzyme inhibition data showed that the amide formation at position 6 (compounds **10** and **12**) had a detrimental effect on the inhibition of *E. coli* topoisomerase IV (IC₅₀ values above 10 μM) and resulted in weak inhibition of *E. coli* DNA gyrase with IC₅₀ values in the low micromolar range. These results are consistent with our previous study in which bioisosteric replacements of the carboxylate group or its substitution resulted in weaker DNA gyrase and topoisomerase IV inhibition.¹⁴ In the same study, we also showed that substituents at position 4 of the benzothiazole scaffold in potent inhibitors can have different chemical properties. These observations were confirmed with compounds **18a** and **18b**, which carried the siderophore mimic at position 4. These compounds inhibited *E. coli* DNA gyrase in the low nanomolar range and displayed only slightly weaker *E. coli* topoisomerase IV inhibition than did the parent compound **B** (Table 1). With compounds **18a** and **18b**, we confirmed our hypothesis that it is possible to maintain potent enzyme





Scheme 1 Synthesis of siderophore fragments **4** and **6**. Reagents and conditions: (a) 4-methoxybenzyl chloride, K_2CO_3 , dry DMF, 60 °C, 4 h (45.6%); (b) methanesulfonyl chloride, Et_3N , DCM, 20 °C, 4 h; (c) NaBr, DMF, 20 °C, 16 h (69.0% over two steps); (d) NaN_3 , KI, DMF, 20 °C, 20 min (84.4%); (e) PPh_3 , MeOH, 20 °C, 1 h (37.1%). PMB – *p*-methoxybenzyl.

inhibition after introduction of the siderophore mimic into the structure of the GyrB/ParE inhibitor.


Molecular modeling

The binding modes of **18b** in the ATP-binding sites of *E. coli* GyrB and ParE were studied by a combination of molecular docking calculations, molecular dynamics simulation and interaction analyzes. Inhibitor **18b** was first docked to *E. coli* GyrB (PDB entry: 4WUB⁴³) and ParE (PDB entry: 1S16 (ref. 44)) ATP-binding sites. These two co-crystal structures were used because they contain the flexible loop in the lipophilic floor of the enzymes that can interact with the substituent at position 4 of the benzothiazole core. The binding mode of **18b** was consistent with the co-crystal structures of benzothiazole-based GyrB/ParE inhibitors in complex with *S. aureus* GyrB. In *E. coli* GyrB, the pyrrolamide moiety formed hydrogen bonds with Asp73 and Thr165 and several hydrophobic interactions in the hydrophobic pocket. A salt bridge was formed between the 6-

carboxylate group and Arg136 and a cation- π interaction was formed between the benzothiazole ring and Arg76 guanidinium group. The docking binding mode of **18b** in complex with *E. coli* GyrB was used as a starting point for the 100 ns MD simulation. The MD trajectory was then analyzed using structure-based pharmacophore modeling in LigandScout. Analysis of the MD simulation trajectory showed that the siderophore mimic bound at position 4 of the benzothiazole core is quite flexible and forms hydrogen bonds with the Ala100-Tyr109 residues of the flexible loop. It forms additional π -stacking with the Phe104 side chain (Fig. 2), which is present in 18% of the simulation time. This analysis clearly showed the important contribution of the siderophore mimic to the binding affinity.


Antibacterial activity

We also tested the antibacterial activity of the siderophore mimic-bearing GyrB/ParE inhibitors **10**, **12** and **18b** against wild type G – *E. coli*, *P. aeruginosa* and *A. baumannii* in iron-depleted



Scheme 2 Synthesis of siderophore mimic conjugates **10** and **12**. Reagents and conditions: (a) EDC, HOEt, NMM, DMF, 0 °C to 20 °C, 16 h (72.4%); (b) 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one, Na_2CO_3 , DMF, 80 °C, 16 h (75.0%); (c) 1 M HCl in acetic acid, acetic acid, 20 °C, 16 h (84.8–88.9%); (d) NH_3 (25% aq. solution), MeOH, 70 °C, 48 h (87.9%).





Scheme 3 Synthesis of siderophore mimic conjugates **18a** and **18b**. Reagents and conditions: (a) K_2CO_3 , CH_3CN , $60\text{ }^\circ\text{C}$, 16 h (60.5%); (b) 2,2,2-trichloro-1-(4,5-dibromo-1*H*-pyrrol-2-yl)ethan-1-one (for **15a**) or 2,2,2-trichloro-1-(3,4-dichloro-5-methyl-1*H*-pyrrol-2-yl)ethan-1-one (for **15b**), Na_2CO_3 , DMF, $80\text{ }^\circ\text{C}$, 16 h (24.5–77.8%); (c) NH_3 (25% aq. solution), MeOH , $60\text{ }^\circ\text{C}$, 3 h, then $20\text{ }^\circ\text{C}$, 16 h (or $60\text{ }^\circ\text{C}$, 16 h – for **16b**) (32.0–33.0%); (d) 1–2 M NaOH , 1,4-dioxane (for **17a**) or MeOH (for **17b**), $40\text{ }^\circ\text{C}$, 16 h (33.3–63.7%); (e) 1 M HCl in acetic acid, acetic acid, $20\text{ }^\circ\text{C}$, 40 h (52.4–62.3%). PMB = *p*-methoxybenzyl.

cation-adjusted Mueller Hinton broth (ID-CAMHB) and iron-supplemented CAMHB broth (CAMHB + Fe). Cefiderocol, a siderophore cephalosporin, was used as a positive control. Compound **18a** was only tested on *E. coli* in both media

conditions. Iron-depleted conditions were used to determine the effects of the attached siderophore mimics on antibacterial activities, since bacteria under low iron conditions produce and secrete siderophores to take up iron from the extracellular




Fig. 2 Representative snapshot from molecular dynamics trajectory. (A) Compound **18b** (in grey sticks) in the binding site of *E. coli* GyrB (PDB entry: 4WUB). (B) Schematic representation of the pharmacophore model. Pharmacophore features are presented as follows: hydrophobic features as yellow spheres, hydrogen bond donor as a green arrow, hydrogen bond acceptor as a red arrow, negative ionizable as a red star and aromatic rings as a blue disc.

Table 2 Antibacterial activity of **10**, **12**, **18a**, and **18b** against *E. coli*, *P. aeruginosa* and *A. baumannii*^a

	<i>P. aeruginosa</i>		<i>A. baumannii</i>		<i>E. coli</i> JW5503			
	ATCC	ATCC	ATCC	ATCC				
	25922	27853	19606					
	–Fe	+Fe	–Fe	+Fe	–Fe	+Fe	–Fe	+Fe
10	>50	>50	>50	>50	>50	>50	>50	>50
12	>50	>50	>50	>50	>50	>50	>50	>50
18a	>50	>50	n.t.	n.t.	n.t.	n.t.	n.t.	n.t.
18b	>50	>50	>50	>50	>50	12.5	25	
Cefiderocol	0.25	0.25	0.25	1	0.25	2	0.0625	0.125

^a –Fe: iron depleted cation adjusted Mueller Hinton broth media (ID-CAMHB), +Fe: cation adjusted Mueller Hinton broth media + Fe (CAMHB + Fe), n.t.: not tested.

environment.³² In general, compounds **10**, **12**, **18a** and **18b** displayed rather weak antibacterial activity at 50 μ M in iron-supplemented and iron-depleted media, which indicated MIC values > 50 μ M (Table 2). We have previously observed that our benzothiazole GyrB/ParE inhibitors are strongly effluxed from the G– bacterial cells and that this effect is especially pronounced in *E. coli*.¹⁴ Therefore, compounds **10**, **12**, and **18b** were also tested against *E. coli* JW5503, which is a *tolC* deletion mutant strain with a defective efflux pump. Compound **18b** showed an MIC value of 25 μ M (12.7 μ g mL^{–1}) under iron-supplemented conditions. Improvement of antibacterial




Fig. 4 The stacking plot of NMR spectra of the pyridinone proton at 7.3 ppm of **18b** after stepwise addition of FeCl_3 to a DMSO solution of **18b**.

activity of **18b** against efflux-defective *E. coli* JW5503 with an MIC value of 12.5 μ M (6.37 μ g mL^{–1}) was observed under iron-depleted conditions. For cefiderocol, which was used as a positive control, similar twofold improvement of antibacterial activity was observed in iron-depleted medium (Table 2). These results demonstrate the contribution of the siderophore mimic to cell wall permeation rendering to a more potent antibacterial activity of **18b**, however, efflux remains to be a major issue of the benzothiazole GyrB/ParE inhibitors. The antibacterial activity of **18b** was weaker than that of parent compounds **A** and **B**, suggesting that the incorporation of the siderophore mimic has a limited contribution. In our recent study, we also showed that benzothiazole-based GyrB inhibitors with potent activity against G– strains have a topological surface area (TPSA) of less than 120 \AA^2 .^{36,37} Replacement of the phenyl ring of inhibitor **B** (TPSA




Fig. 3 The stacking plot of NMR spectra of **18b** after stepwise addition of FeCl_3 to a DMSO solution of **18b**. The inset shows the aromatic region of **18b**.



= 100.0 Å²) by the oxygen- and nitrogen-rich siderophore mimic in **18b** results in a significantly higher TPSA of 149.4 Å², which may be one of the reasons for the weaker antibacterial activity of **18b** despite the presence of the siderophore mimic in its structure.

NMR spectroscopy of **18b**-iron(III) complex

Given the improved antibacterial activity of **18b** against the *E. coli* JW5503 in iron-depleted medium, its potential for chelation of iron(III) was studied by NMR spectroscopy. To a DMSO-*d*₆ solution of **18b**, FeCl₃ in steps of 0.1 equivalents of Fe³⁺ was added (Fig. 3). A very small shift was observed for all the resonances in the spectrum with increasing Fe³⁺ concentration (Fig. 3), which can be attributed to the strong acidity of the ferric chloride solution. In fact, the hydroxypyridinone resonances showed the largest shift among **18b** resonances. However, while all the resonances did not change their profile along this short titration (apart from the progressive broadening due to the increasing concentration of the paramagnetic Fe³⁺ ion in solution), the two hydroxypyridinone resonances showed a difference. Fig. 4 shows how the single resonance (red spectrum) progressively broadened (orange) and passed through a clear convolution of two components (yellow) at about 0.2 equivalents of Fe³⁺. Then, the signal progressively returned to a single component (green) and started to progressively broaden (blue). This is the typical trend observed when two forms are in a relatively slow exchange, with the molar fraction of the first one progressively decreasing from 1 to 0, while the other progressively and complementarily increases from 0 to 1. One of the two forms is the free ligand, which is maximum in the absence of ferric ions. With increasing the latter, the free ligand is progressively transformed to the ligand–metal complex. Our experiment showed that the signals for a free ligand disappeared by the addition of 0.4 equivalents of FeCl₃, with the half-equivalence point around 0.2. This clearly suggests the formation of complexes with stoichiometry L₃M (where L is the ligand and M the metal). Moreover, in the range investigated (ligand excess), all of the other resonances appeared to be insensitive to the formation of the complex, which shows that only the hydroxypyridinone moiety is exploited in the complex formation. These two observations agree with each other. Each hydroxypyridinone is expected to use two O donors to coordinate the metal ion, thus, in the complex L₃M, the three hydroxypyridinones are enough to complete the typical octahedral configuration around Fe³⁺.

Conclusions

We have prepared new conjugates of our antibacterially active GyrB/ParE inhibitors with 2-(aminomethyl)-5-hydroxy-4H-pyran-4-one and 2-(aminomethyl)-5-hydroxypyridin-4(1H)-one siderophore mimics. These mimics were attached to two different positions and their incorporation to the position 4 of the benzothiazole scaffold resulted in potent DNA gyrase inhibition, whereas the inhibition of topoisomerase IV was slightly weaker compared with the parent inhibitors. The most potent

inhibitor **18b** showed a twofold enhancement of antibacterial activity against the efflux-defective *E. coli* strain JW5503, but was only weakly active against wild-type *E. coli*, *P. aeruginosa* and *A. baumannii*. The results with wild-type and efflux-defective *E. coli* strains indicated that efflux remains a problem for benzothiazole-based GyrB/ParE inhibitors and will be the focus of future optimization.

Experimental section

Chemicals were obtained from Acros Organics (Geel, Belgium), Sigma-Aldrich (St Louis, MO, USA), Apollo Scientific Ltd (Stockport, UK), Fluorochem Ltd (Derbyshire, UK), and Enamine Ltd (Kyiv, Ukraine) and were used without further purification. Analytical TLC was performed on silica gel Merck 60 F254 plates (0.25 mm), using visualization with UV light and spray reagents. Column chromatography was carried out on silica gel 60 (particle size, 240–400 mesh). ¹H and ¹³C NMR spectra were recorded at 400 MHz and 101 MHz, respectively, on a Bruker AVANCE III 400 spectrometer (Bruker Corporation, Billerica, MA, USA) in DMSO-*d*₆ or CDCl₃ solutions, with TMS as the internal standard. Mass spectra were obtained using an ADVION expression CMS^L mass spectrometer (Advion Inc., Ithaca, USA) and high-resolution mass spectra were obtained using VG Analytical Autospec Q Micromass mass spectrometer (Fisons, VG Analytical, Manchester, UK) (compounds 5, 8–12) or Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) (compounds **18a** and **18b**). HPLC purity analyses were performed on a 1260 Infinity II LC system (Agilent Technologies Inc., Santa Clara, CA, USA). A Waters XBridge C18 column was used (3.5 µm, 4.6 mm × 150 mm), with flow rate of 1.5 mL min⁻¹ and sample injection volume of 10 µL. The mobile phase consisted of acetonitrile (solvent A) and 0.1% formic acid in 1% acetonitrile in ultrapure water (solvent B). The gradient (defined for solvent A) was: 0–1.0 min, 25%; 1.0–6.0 min, 25–98%; 6.0–6.5 min, 98%; 6.5–7.5 min, 98–25%; 7.5–10.5 min, 25%. All active tested compounds were more than 95% pure as established by HPLC, unless indicated otherwise.

Synthesis of compounds

2-(Hydroxymethyl)-5-((4-methoxybenzyl)oxy)-4H-pyran-4-one (2).²⁵ 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one (**1**, 5.00 g, 35.2 mmol) and K₂CO₃ (10.7 g, 77.4 mmol) were suspended in DMF (65 mL), flushed with argon and heated to 60 °C. 4-Methoxybenzyl chloride (5.25 mL, 38.7 mmol) was added dropwise and the reaction mixture was stirred at 60 °C for 4 h. The reaction mixture was poured on a mixture of water and ice (1 : 1, 500 mL) and left overnight. The formed crystals were filtered off and dried. Yield: 4.21 g (45.6%); orange crystals; mp: 112 °C.

5-((4-Methoxybenzyl)oxy)-4-oxo-4H-pyran-2-yl)methyl hydrogen sulfate (3). To a solution of **2** (4.12 g, 15.7 mmol) in DCM (55 mL) cooled on an ice bath triethylamine (4.40 mL, 31.7 mmol) was added and the mixture was stirred for 20 min. The reaction mixture was heated to rt, methanesulfonyl chloride



(1.20 mL, 15.5 mmol) was added and the reaction mixture was stirred at rt for 3 h. After the reaction was finished dichloromethane (30 mL) was added and the organic phase was washed with brine (140 mL). Organic phase was dried over Na_2SO_4 , filtered and the solvent removed *in vacuo*. The crude oily product was used in the next step without further purification.

2-(Bromomethyl)-5-((4-methoxybenzyl)oxy)-4*H*-pyran-4-one

(4). To a suspension of 3 (4.12 g, 12.04 mmol) in DMF (10 mL) NaBr (3.23 g, 31.4 mmol) was added and the reaction mixture was stirred at rt overnight. Ethyl acetate (80 mL) was added and the organic phase was washed with brine (2×100 mL), dried over Na_2SO_4 , filtered and the solvent removed *in vacuo*. The crude product was purified with flash column chromatography using dichloromethane/methanol (20 : 1) as eluent. Yield: 2.70 g (69.0%); white crystals; mp: 107 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ [ppm] 3.76 (s, 3H), 4.56 (s, 2H), 4.86 (s, 2H), 6.57 (s, 1H), 6.95 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 8.26 (s, 1H).

2-(Azidomethyl)-5-((4-methoxybenzyl)oxy)-4*H*-pyran-4-one

(5). To a suspension of 3 (3.29 g, 9.66 mmol) in DMF (10 mL) NaN_3 (1.26 g, 19.3 mmol) and catalytic amount of KI were added and the reaction mixture was stirred at rt for 20 min. Ethyl acetate (80 mL) was added and the organic phase was washed with 1% citric acid (2×50 mL) and brine (50 mL), dried over Na_2SO_4 , filtered and the solvent removed *in vacuo*. Yield: 2.33 g (84.4%); light brown oil; mp: 107 °C. ^1H NMR (400 MHz, CDCl_3) δ [ppm] 3.83 (s, 3H), 4.16 (s, 2H), 5.04 (s, 2H), 6.43 (s, 1H), 6.92 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.8 Hz, 2H), 7.56 (s, 1H). HRMS (ESI $^+$) m/z for $\text{C}_{14}\text{H}_{14}\text{N}_3\text{O}_4$ ([M + H] $^+$): calculated 288.0979, found 288.0978.

2-(Aminomethyl)-5-((4-methoxybenzyl)oxy)-4*H*-pyran-4-one

(6). To a solution of 5 (2.33 g, 8.11 mmol) in methanol (20 mL) triphenylphosphine (3.19 g, 12.2 mmol) was added and the reaction mixture was stirred at rt for 1 h. Water (5 mL) was added and a formed precipitate was filtered off. Mother liquid was collected and methanol was removed *in vacuo*. To the residue 1 M HCl was added to pH 3 and the acidic water phase was extracted with ethyl acetate (2×100 mL). The pH of the water phase was adjusted to 12 using 1 M NaOH and alkaline water phase was extracted with ethyl acetate (2×100 mL). Combined organic phases were dried over Na_2SO_4 , filtered and the solvent removed *in vacuo*. Yield: 0.786 g (37.1%); brown oil. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ [ppm] 3.54 (s, 2H), 3.77 (s, 3H), 4.86 (s, 2H), 6.38 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 8.8 Hz, 2H), 8.11 (s, 1H), signal for NH_2 group is not seen. HRMS (ESI $^+$) m/z for $\text{C}_{14}\text{H}_{16}\text{NO}_4$ ([M + H] $^+$): calculated 262.1074, found 262.1076.

2-Amino-N-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methyl)benzo[d]thiazole-6-carboxamide (8). To the solution of 7 (362 mg, 1.86 mmol) in DMF (5 mL) EDC (535 mg, 2.23 mmol), HOBT (327 mg, 2.42 mmol) and *N*-methylmorpholine (409 μL , 3.72 mmol) were added and the reaction mixture was stirred on an ice bath for 20 min. 6 (487 mg, 1.86 mmol) was added and the reaction mixture was stirred at rt overnight. The precipitate in the reaction mixture was filtered off and dried to afford 8 as pale-yellow powder. Yield: 590 mg (72.4%); pale yellow powder; mp: 185–191 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ [ppm] 3.76 (s, 3H), 4.34 (d, J = 5.7 Hz, 2H), 4.85 (s, 2H), 6.26 (s, 1H), 6.95 (d, J =

6.8 Hz, 2H), 7.31–7.42 (m, 3H), 8.19 (s, 1H), 7.78 (dd, J = 1.9, 8.4 Hz, 1H), 7.82 (s, 2H), 8.22 (d, J = 1.8 Hz, 1H), 8.98 (t, J = 5.8 Hz, 1H). HRMS (ESI $^+$) m/z for $\text{C}_{22}\text{H}_{20}\text{N}_3\text{O}_5\text{S}$ ([M + H] $^+$): calculated 438.1118, found 438.1119.

General procedure A. Synthesis of compounds 9 and 15a,b (with 9 as example). To the solution of 8 (198 mg, 0.453 mmol) and 2,2,2-trichloro-1-(4,5-dibromo-1*H*-pyrrol-2-yl)ethan-1-one (167 mg, 0.453 mmol) in DMF (2 mL) Na_2CO_3 (48 mg, 0.453 mmol) was added and the reaction mixture was stirred at 80 °C overnight. Ethyl acetate (20 mL) and 1% citric acid (10 mL) were added and the precipitate that formed was filtered off and dried to give 9 (234 mg) as grey powder.

2-(4,5-Dibromo-1*H*-pyrrole-2-carboxamido)-N-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methyl)benzo[d]thiazole-6-carboxamide (9). Yield: 234 mg (75.0%); grey powder; mp > 300 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ [ppm] 3.77 (s, 3H), 4.39 (d, J = 5.6 Hz, 2H), 4.86 (s, 2H), 6.31 (s, 1H), 6.95 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.55 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.99 (dd, J = 1.8, 8.5 Hz, 1H), 8.20 (s, 1H), 8.55 (d, 1H, J = 1.8 Hz), 9.15 (t, 1H, J = 5.7 Hz), 12.82 (s, 1H), 13.28 (s, 1H). HRMS (ESI $^+$) m/z for $\text{C}_{27}\text{H}_{21}\text{Br}_2\text{N}_4\text{O}_6\text{S}$ ([M + H] $^+$): calculated 686.9543, found 686.9385.

General procedure B. Synthesis of compounds 10, 12 and 18a,b (with 10 as example). To the solution of 9 (79 mg, 0.115 mmol) in acetic acid (3 mL) 1 M HCl in acetic acid (2.30 mL, 2.30 mmol) was added and the reaction mixture was stirred at rt overnight. The solvent was removed *in vacuo*, to the residue diethyl ether (10 mL) was added, sonicated and removed *in vacuo*. The procedure with diethyl ether was repeated 4 times. Finally, diethyl ether (10 mL) was added, sonicated and the resulting suspension was filtered to give the product (58 mg) as grey powder.

2-(4,5-Dibromo-1*H*-pyrrole-2-carboxamido)-N-((5-hydroxy-4-oxo-4*H*-pyran-2-yl)methyl)benzo[d]thiazole-6-carboxamide (10). Yield: 58 mg (88.9%); grey powder; mp > 300 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ [ppm] 4.38 (d, J = 5.5 Hz, 2H), 6.33 (s, 1H), 7.55 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.99 (dd, J = 1.8, 8.5 Hz, 1H), 8.08 (s, 1H), 8.57 (d, J = 1.7 Hz, 1H), 9.17 (s, 1H), 12.81 (s, 1H), 13.29 (d, J = 2.7 Hz, 1H), signal for NH group is missing. HRMS (ESI $^+$) m/z for $\text{C}_{19}\text{H}_{13}\text{Br}_2\text{N}_4\text{O}_5\text{S}$ ([M + H] $^+$): calculated 566.8968, found 566.8809. HPLC: t_r 5.38 min (81.5% at 254 nm).

General procedure C. Synthesis of compounds 11, 16a,b (with 11 as example). To the suspension of 9 (100 mg, 0.145 mmol) in methanol (10 mL) 25% aq. NH_3 solution (10 mL, 111 mmol) was added and the reaction mixture was stirred at 70 °C overnight. Methanol was removed *in vacuo*, the precipitate in the remaining mixture was filtered off and dried to give the product (88 mg) as light grey powder.

2-(4,5-Dibromo-1*H*-pyrrole-2-carboxamido)-N-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methyl)benzo[d]thiazole-6-carboxamide (11). Yield: 88 mg (87.9%); light grey powder; mp: 237–242 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ [ppm] 3.76 (s, 3H), 4.43 (s, 2H), 4.94 (s, 2H), 6.11 (s, 1H), 6.94 (d, J = 8.7 Hz, 2H), 7.29–7.45 (m, 3H), 7.54 (s, 1H), 7.84 (d, J = 8.5 Hz, 1H), 8.00 (dd, J = 1.8, 8.6 Hz, 1H), 8.56 (d, 1H, J = 1.8 Hz), 9.09 (t, 1H, J = 5.8 Hz), 11.22 (s, 1H), 12.82 (s, 1H), 13.28 (s,



1H). HRMS (ESI⁺) *m/z* for C₂₇H₂₂Br₂N₅O₅S ([M + H]⁺): calculated 685.9703, found 685.9544.

2-(4,5-Dibromo-1*H*-pyrrole-2-carboxamido)-*N*-(5-hydroxy-4-oxo-1,4-dihydropyridin-2-yl)methylbenzo[*d*]thiazole-6-carboxamide (12). Synthesized according to General procedure B using 2-(4,5-dibromo-1*H*-pyrrole-2-carboxamido)-*N*-(5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methylbenzo[*d*]thiazole-6-carboxamide (11, 70 mg, 0.102 mmol) as reactant. Yield: 49 mg (84.8%); purple solid; mp > 300 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ [ppm] 4.65 (d, *J* = 5.6 Hz, 2H), 7.22 (s, 1H), 7.55 (s, 1H), 7.83 (d, *J* = 8.5 Hz, 1H), 7.99 (dd, *J* = 1.6, 8.5 Hz, 1H), 8.08 (s, 1H), 8.57 (d, *J* = 1.7 Hz, 1H), 9.41 (t, *J* = 5.7 Hz, 1H), 12.82 (s, 1H), 13.29 (d, *J* = 2.7 Hz, 1H), 14.36 (s, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ [ppm] 99.63, 109.39, 110.83, 116.93, 117.22, 120.31, 122.10, 126.07, 126.16, 126.39, 129.12, 132.03, 144.68, 147.40, 151.41, 157.84, 161.25, 162.05, 166.98. HRMS (ESI⁻) *m/z* for C₁₄H₁₃Br₂N₅O₄S ([M - H]⁻): calculated 565.9128, found 565.8969. HPLC: *t*_r 5.25 min (83.6% at 254 nm).

Methyl 2-amino-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (14). To a solution of methyl 2-amino-4-hydroxybenzo[*d*]thiazole-6-carboxylate (1.02 g, 3.12 mmol) in acetonitrile (40 mL), K₂CO₃ (0.860 g, 6.22 mmol) and 2-(bromomethyl)-5-((4-methoxybenzyl)oxy)-4*H*-pyran-4-one (4, 0.700 g, 3.12 mmol) were added. Reaction was stirred under reflux overnight. Solvent was removed under reduced pressure and the crude residue dissolved in ethyl acetate (140 mL). Organic phase was then successively washed with 10% citric acid (180 mL) and saturated NaHCO₃ solution (180 mL). The precipitated product was filtered off. Solvent was removed under reduced pressure and crude product purified by column chromatography using dichloromethane/methanol (20 : 1) as eluent. Yield: 0.89 g (60.5%); brown solid; mp: 126 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ [ppm] 3.76 (s, 3H), 3.83 (s, 3H), 4.88 (s, 2H), 5.17 (s, 2H), 6.57 (s, 1H), 6.96 (d, *J* = 8.7 Hz, 2H), 7.35 (d, *J* = 8.7 Hz, 2H), 7.44 (d, *J* = 1.5 Hz, 1H), 7.99 (s, 2H), 8.02 (d, *J* = 1.5 Hz, 1H), 8.27 (s, 1H).

Methyl 2-(4,5-dibromo-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (15a). Synthesized according to General procedure A using methyl 2-amino-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (14, 350 mg, 0.75 mmol). Yield: 420 mg (77.8%); beige solid; mp: 254 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ [ppm] 3.78 (s, 3H), 3.89 (s, 3H), 4.90 (s, 2H), 5.26 (s, 2H), 6.64 (s, 1H), 6.97 (d, *J* = 8.7 Hz, 2H), 7.36 (d, *J* = 8.6 Hz, 2H), 7.57 (d, *J* = 2.7 Hz, 1H), 7.60 (d, 1H), 8.31 (d, 1H), 8.35 (s, 1H), 13.00 (s, 1H), 13.28 (s, 1H). MS (ESI) *m/z* = 643.8 ([M + H]⁺).

Methyl 2-(3,4-dichloro-5-methyl-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (15b). Synthesized according to General procedure A using methyl 2-amino-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (14, 400 mg, 0.854 mmol) and 2,2,2-trichloro-1-(3,4-dichloro-5-methyl-1*H*-pyrrol-2-yl)ethan-1-one (166 mg, 0.854 mmol) as reactants. The precipitate after filtration contained a mixture of the starting compound (14) and the product. To separate, the mixture was suspended in methanol, heated and

the precipitate which contained the starting compound was filtered off. The procedure was repeated three times to wash the product into methanol. Methanol was then left to cool at room temperature overnight, the product precipitated and was filtered off and dried. Yield: 135 mg (24.5%); light grey solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ [ppm] 2.27 (s, 3H), 3.77 (s, 3H), 3.89 (s, 3H), 4.90 (s, 2H), 5.27 (s, 2H), 6.65 (s, 1H), 6.96 (d, *J* = 8.7 Hz, 2H), 7.36 (d, *J* = 8.6 Hz, 2H), 7.60 (s, 1H), 8.30 (s, 1H), 8.34 (s, 1H), 12.25 (s, 2H). HRMS (ESI⁺) *m/z* for C₂₉H₂₄Cl₂N₃O₈S ([M + H]⁺): calculated 644.0656, found 644.0652.

Methyl 2-(4,5-dibromo-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (16a). Synthesized according to General procedure C using methyl 2-(4,5-dibromo-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (15a, 150 mg, 0.12 mmol). The crude product was purified with flash column chromatography using dichloromethane/methanol (9 : 1) as eluent. Compound was obtained as a mixture of tautomers and ¹H NMR signals could not be unambiguously assigned. Yield: 48 mg (32.0%); beige solid; mp > 300 °C. MS (ESI) *m/z* = 717.3 ([M + H]⁺).

Methyl 2-(3,4-dichloro-5-methyl-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (16b). Synthesized according to General procedure C using methyl 2-(3,4-dichloro-5-methyl-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-4*H*-pyran-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylate (15b, 279 mg, 0.432 mmol). The crude product was suspended in ethyl acetate and a drop of methanol, filtered off and dried to give 60 mg of the product as a brown solid. The mother liquid was additionally purified with flash column chromatography using dichloromethane/methanol (20 : 1 → 9 : 1) as eluent to give another 32 mg of the product as white crystals. Compound was obtained as a mixture of tautomers and ¹H NMR signals could not be unambiguously assigned. Yield: 92 mg (33.0%); brown solid and white crystals. MS (ESI) *m/z* = 643.0 ([M + H]⁺).

2-(4,5-Dibromo-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylic acid (17a). To a suspension of 16a (40 mg, 0.060 mmol) in 1,4-dioxane 2 M NaOH (140 μ L, 0.280 mmol) was added and the reaction mixture was stirred at 60 °C overnight. Additional 140 μ L of 2 M NaOH were added and the reaction mixture was stirred at 60 °C for another 3 h. The solvent was evaporated *in vacuo*, the residue was acidified with 1 M HCl and the precipitated product was filtered off and dried. Compound was obtained as a mixture of tautomers and ¹H NMR signals could not be unambiguously assigned. Yield: 25 mg (63.7%); beige solid; mp > 300 °C. MS (ESI) *m/z* = 703.0 ([M - H]⁻).

2-(3,4-Dichloro-5-methyl-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylic acid (17b). To a suspension of 16b (92 mg, 0.150 mmol) in methanol 1 M NaOH (750 μ L, 0.750 mmol) was added and the reaction mixture was stirred at 60 °C overnight. Additional 750 μ L of 1 M NaOH were added and the reaction mixture was stirred at 60 °C for another 3 h. The



solvent was evaporated *in vacuo*, the residue was acidified with 1 M HCl and the precipitated product was filtered off and dried. Compound was obtained as a mixture of tautomers and ¹H NMR signals could not be unambiguously assigned. Yield: 30 mg (33.3%); brown solid; mp > 300 °C. MS (ESI) *m/z* = 627.0 ([M – H][–]).

2-(4,5-Dibromo-1*H*-pyrrole-2-carboxamido)-4-((5-hydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylic acid (18a). Synthesized according to General procedure B using 2-(4,5-dibromo-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylic acid (17a, 23 mg, 0.033 mmol) as reactant and stirring the reaction mixture for 48 h. Yield: 10 mg (52.4%), pink solid; mp > 300 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ [ppm] 5.38 (s, 2H), 7.13 (s, 1H), 7.55 (s, 1H), 7.59 (d, *J* = 1.3 Hz, 2H), 8.02 (s, 1H), 8.32 (d, *J* = 1.3 Hz, 1H), 12.94 (s, 1H), 13.29 (s, 1H), signals for NH and COOH groups are missing. HRMS (ESI[–]) *m/z* for C₁₉H₁₁Br₂N₄O₆S ([M – H][–]): calculated 580.8773, found 580.8772. HPLC: *t*_r 5.72 min (95.9% at 254 nm).

2-(3,4-Dichloro-5-methyl-1*H*-pyrrole-2-carboxamido)-4-((5-hydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylic acid (18b). Synthesized according to General procedure B using 2-(3,4-dichloro-5-methyl-1*H*-pyrrole-2-carboxamido)-4-((5-((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)benzo[*d*]thiazole-6-carboxylic acid (17b, 27 mg, 0.043 mmol) as reactant. 60 equiv. of 1 M HCl in acetic acid were used and the reaction mixture was stirred in a pressure tube at 50 °C for 1 week. The crude product was suspended in methanol, filtered off and dried. Yield: 13.6 mg (62.3%); beige solid; mp > 300 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ [ppm] 2.27 (s, 3H), 5.50 (s, 2H), 7.43 (s, 1H), 7.61 (d, *J* = 1.4 Hz, 1H), 8.23 (s, 1H), 8.34 (d, *J* = 1.4 Hz, 1H), 11.12 (s, 1H), 12.12 (s, 1H), 12.41 (s, 1H), signals for NH and COOH groups are missing. HRMS (ESI[–]) *m/z* for C₂₀H₁₃Cl₂N₄O₆S ([M – H][–]): calculated 506.9938, found 506.9943. HPLC: *t*_r 5.11 min (90.0% at 254 nm).

Determination of inhibitory activities against *E. coli* DNA gyrase and topoisomerase IV

The assays for determination of IC₅₀ against *E. coli* DNA gyrase and topoisomerase IV were performed according to previously reported procedures.²³ IC₅₀ values were determined with seven concentrations of the inhibitors. GraphPad Prism program was used for calculating an IC₅₀ value, which represents the concentration of inhibitor where the activity of the enzyme is reduced by 50%. IC₅₀ values were determined in three independent measurements, and their average value is given as a final result.

Determination of antibacterial activities

The clinical microbiology control strains of *E. coli* (ATCC 25922), *P. aeruginosa* (ATCC 27853) and *A. baumannii* (ATCC 19606) were obtained from Microbiologics Inc. (St. Cloud, MN, USA). The single-gene knock-out mutant strain of *E. coli* JW5503 (*tolC* knock-out) was obtained from the *E. coli* collection of the National BioResource Project at the National Institute of

Genetics (Japan).⁴⁵ To determine the antibacterial activities, broth microdilution assays were carried out in 96-well plates following the Clinical and Laboratory Standards Institute guidelines.⁴⁶ Compounds were prepared as 100% DMSO stock solutions. The final concentration of DMSO was 1% and had no effect on the growth of bacteria. Preliminary screening was performed at 50 μ M, and growth inhibition was measured after 24 h incubation at 37 °C. For compounds displaying >90% growth inhibition in the preliminary assay, MIC values were determined in dose-response assays (from at least two independent experiments, each with three replicates per concentration). Cation-adjusted Mueller-Hinton broth (CAMHB, BD) was used in all assays. CAMHB was prepared according to manufacturer's instructions and iron-depleted CAMHB (ID-CAMHB) according to CLSI guidelines. ID-CAMHB was used in order to mimic the conditions faced by bacteria during human infections, and induces the ferric iron transport. ID-CAMHB was prepared by adding 100 g of Chelex 100 resin (Bio-Rad) to 1 L of autoclaved CAMHB and stirred for 2 h at room temperature, in order to remove cations from the medium. Then, broth was filtered using a 0.2 μ m filter to remove the resin and pH adjusted to 7.3 using 5 M hydrochloric acid. ID-CAMHB was then supplemented with calcium (CaCl₂), magnesium (MgCl₂) and zinc (ZnSO₄) to final concentrations of 22.5 μ g mL^{–1}, 11.25 μ g mL^{–1} and 0.56 μ g mL^{–1}, respectively, and filtered again. To evaluate the effect of iron concentration on antibacterial effect of compounds, an appropriate amount of iron(III) chloride was added to ID-CAMHB, and this supplemented media was used as control CAMHB. The iron concentration in CAMHB and ID-CAMHB were approximately 0.2 mg L^{–1} and \leq 0.03 mg L^{–1}, respectively. Cefiderocol, a positive control, MICs were determined against *E. coli*, *P. aeruginosa* and *A. baumannii*, and used as positive control in the assays. Cefiderocol was purchased from MedChemExpress Europe.

Nuclear magnetic resonance. Spectra were recorded at 300 K on a Bruker Avance III HD 600 (Bruker, Billerica, MA, USA) operating at a ¹H frequency of 600 MHz. The one-dimensional ¹H spectra were acquired with a pulse of 10.0 μ s (90°), 3 s recycle delay, 1.5 s acquisition time, and 16 transients over a spectral window of 9000 Hz. The titrations of **18b** in DMSO-*d*₆ were performed with FeCl₃ in steps of 0.1 equivalents of Fe³⁺ up to 0.4, at constant ligand concentration in the 2–3 mM range.

Molecular docking. Molecular docking calculations were performed in Schrödinger Release 2022-1 (Schrödinger, LLC, New York, NY, USA, 2022). Crystal structures of *E. coli* GyrB (PDB entry: 4DUH) and ParE (PDB entry: 1S16) were retrieved from Protein Data Bank. Proteins were then prepared by Protein Preparation Wizard using default settings. Receptor grids were calculated for the ligand-binding sites and designed compounds were docked using Glide XP protocol as implemented in Schrödinger Release 2022-1 (Glide, Schrödinger, LLC, New York, NY, USA, 2022). The highest ranked docking pose was used for visualization.

Molecular dynamics simulations. MD simulation of **18b** in complex with *E. coli* GyrB was performed using NAMD package (version 2.9)⁴⁷ and the CHARMM36m⁴⁸ force field. Removal of potential steric clashes and optimization of the atomic



coordinates of the docking complex were first performed by steepest descent (10 000 steps) and adopted basis Newton-Raphson (10 000 steps) energy minimizations. The system for MD simulation was prepared using CHARMM-GUI.^{49,50} Molecular mechanics parameters for compound **18b** were estimated using the ParamChem tool.^{51–53} Structure of the **18b**-GyrB complex was first embedded in a box of TIP3P water molecules. Then the system was neutralized by addition of KCl. The MD simulation was run in the NPT ensemble using the periodic boundary conditions. Temperature (300 K) and pressure (1 atm) were controlled using the Langevin dynamics and Langevin piston methods, respectively. Short-range and long-range forces were calculated every 1 and 2 time steps, respectively, with a time step of 2.0 ps. The smooth particle mesh Ewald method was used to calculate the electrostatic interactions.⁵⁴ The short-range interactions were cut off at 12 Å. All of the chemical bonds between hydrogen and the heavy atoms were held fixed using the SHAKE algorithm.⁵⁵ After equilibration of the complete system for 1 ns, an unconstrained 100 ns production was run.

Structure-based pharmacophore modeling. The 100 ns MD trajectory of *E. coli* GyrB in complex with **18b** was used for pharmacophore feature analysis using LigandScout 4.4 Expert,⁵⁶ which resulted in 1000 structure-based pharmacophore models.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The work was supported by the Slovenian Research Agency (Grant No. P1-0208, J1-3030) and by the Academy of Finland (Grant No. 321551). M. C. thanks for partial support the project INF-ACT funded within the PNRR program.

References

- 1 C. J. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. R. Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. K. Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiù, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. D. Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyaney, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, N. Mturi, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, A. Riddell, T. Roberts, J. V. Robotham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsimakul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek and M. Naghavi, *Lancet*, 2022, **399**, 629–655.
- 2 K. Lewis, *Cell*, 2020, **181**, 29–45.
- 3 J. J. Champoux, *Annu. Rev. Biochem.*, 2001, **70**, 369–413.
- 4 H. Hiasa, *Methods Mol. Biol.*, 2018, **1703**, 47–62.
- 5 T. Tomašić and L. Peterlin Masic, *Curr. Top. Med. Chem.*, 2014, **14**, 130–151.
- 6 A. M. Emmerson and A. M. Jones, *J. Antimicrob. Chemother.*, 2003, **51**(suppl 1), 13–20.
- 7 P. A. Bradford, A. A. Miller, J. O'Donnell and J. P. Mueller, *ACS Infect. Dis.*, 2020, **6**, 1332–1345.
- 8 A. Kolarić, M. Anderluh and N. Minovski, *J. Med. Chem.*, 2020, **63**, 5664–5674.
- 9 G. S. Bisacchi and J. I. Manchester, *ACS Infect. Dis.*, 2015, **1**, 4–41.
- 10 A. K. Talley, A. Thurston, G. Moore, V. K. Gupta, M. Satterfield, E. Manyak, S. Stokes, A. Dane and D. Melnick, *Antimicrob. Agents Chemother.*, 2021, **65**, e0120821.
- 11 A. G. Vandell, S. Inoue, J. Dennie, Y. Nagasawa, R. Gajee, J. Pav, G. Zhang, C. Zamora, N. Masuda and G. Senaldi, *Antimicrob. Agents Chemother.*, 2018, **62**, 025377.
- 12 M. Gjorgjieva, T. Tomašić, M. Barančokova, S. Katsamakas, J. Ilaš, P. Tammela, L. Peterlin Mašić and D. Kikelj, *J. Med. Chem.*, 2016, **59**, 8941–8954.
- 13 A. Nyerges, T. Tomašić, M. Durcik, T. Revesz, P. Szili, G. Draskovits, F. Bogar, Ž. Skok, N. Zidar, J. Ilaš, A. Zega, D. Kikelj, L. Daruka, B. Kintses, B. Vasarhelyi, I. Foldesi, D. Kata, M. Welin, R. Kimbung, D. Focht, L. P. Mašić and C. Pal, *PLoS Biol.*, 2020, **18**, e3000819.
- 14 M. Durcik, Á. Nyerges, Ž. Skok, D. G. Skledar, J. Trontelj, N. Zidar, J. Ilaš, A. Zega, C. D. Cruz, P. Tammela, M. Welin, Y. R. Kimbung, D. Focht, O. Benek, T. Révész, G. Draskovits, P. É. Szili, L. Daruka, C. Pál, D. Kikelj, L. P. Mašić and T. Tomašić, *Eur. J. Med. Chem.*, 2021, **213**, 113200.
- 15 M. Durcik, Ž. Skok, J. Ilaš, N. Zidar, A. Zega, P. É. Szili, G. Draskovits, T. Révész, D. Kikelj, A. Nyerges, C. Pál, L. P. Mašić and T. Tomašić, *Pharmaceutics*, 2021, **13**, 6.
- 16 L. B. Rice, *J. Infect. Dis.*, 2008, **197**, 1079–1081.
- 17 H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg and J. Bartlett, *Clin. Infect. Dis.*, 2009, **48**, 1–12.
- 18 WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed, <https://www.who.int/news/item/27-02-2024-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed>



2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed, accessed May 13, 2017.

19 Centers for Disease Control and Prevention (U.S.), *Antibiotic Resistance Threats in the United States, 2019*, Centers for Disease Control and Prevention (U.S.), 2019.

20 J. Vergalli, I. V. Bodrenko, M. Masi, L. Moynié, S. Acosta-Gutiérrez, J. H. Naismith, A. Davin-Regli, M. Ceccarelli, B. van den Berg, M. Winterhalter and J.-M. Pagès, *Nat. Rev. Microbiol.*, 2020, **18**, 164–176.

21 S. Acosta-Gutiérrez, I. V. Bodrenko and M. Ceccarelli, *Antibiotics*, 2021, **10**, 635.

22 G. L. A. Mislin and I. J. Schalk, *Met. Integr. Biometal Sci.*, 2014, **6**, 408–420.

23 T. Tomašić, S. Katsamakas, Ž. Hodnik, J. Ilaš, M. Brvar, T. Solmajer, S. Montalvão, P. Tammela, M. Banjanac, G. Ergović, M. Anderluh, L. P. Mašić and D. Kikelj, *J. Med. Chem.*, 2015, **58**, 5501–5521.

24 A. Lamut, Ž. Skok, M. Barančoková, L. J. Gutierrez, C. D. Cruz, P. Tammela, G. Draskovits, P. É. Szili, Á. Nyerges, C. Pál, P. Molek, T. Bratkovič, J. Ilaš, N. Zidar, A. Zega, R. D. Enriz, D. Kikelj and T. Tomašić, *Future Med. Chem.*, 2020, **12**, 277–297.

25 A. Lamut, C. D. Cruz, Ž. Skok, M. Barančoková, N. Zidar, A. Zega, L. P. Mašić, J. Ilaš, P. Tammela, D. Kikelj and T. Tomašić, *Bioorg. Chem.*, 2020, **95**, 103550.

26 D. Benedetto Tiz, D. Kikelj and N. Zidar, *Expert Opin. Drug Discovery*, 2018, **13**, 497–507.

27 H. I. Zgurskaya, C. A. López and S. Gnanakaran, *ACS Infect. Dis.*, 2015, **1**, 512–522.

28 A. Nazli, D. L. He, D. Liao, M. Z. I. Khan, C. Huang and Y. He, *Adv. Drug Delivery Rev.*, 2022, **189**, 114502.

29 E. Ahmed and S. J. M. Holmström, *Microb. Biotechnol.*, 2014, **7**, 196–208.

30 R. Golonka, B. S. Yeoh and M. Vijay-Kumar, *J. Innate Immun.*, 2019, **11**, 249–262.

31 U. Bilitewski, J. A. V. Blodgett, A.-K. Duhme-Klair, S. Dallavalle, S. Laschat, A. Routledge and R. Schobert, *Angew. Chem. Int. Ed. Engl.*, 2017, **56**, 14360–14382.

32 E. Gumienna-Kontecka, P. L. Carver, E. Gumienna-Kontecka and P. L. Carver, Building a Trojan Horse: Siderophore-Drug Conjugates for the Treatment of Infectious Diseases, In, *Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic*, De Gruyter, Berlin, Germany, 2019, vol. 19, pp. 331–358.

33 P. Loupias, P. Laumaillé, S. Morandat, L. Mondange, S. Guillier, K. El Kirat, S. Da Nascimento, F. Biot, N. Taudon, A. Dassonville-Klimpt and P. Sonnet, *Eur. J. Med. Chem.*, 2023, **245**, 114921.

34 J. Y. Wu, P. Srinivas and J. M. Pogue, *Infect. Dis. Ther.*, 2020, **9**, 17–40.

35 J. Yao, J. Wang, M. Chen and Y. Cai, *Front. Med.*, 2021, **8**, 741940.

36 A. E. Cotman, M. Durcik, D. Benedetto Tiz, F. Fulgheri, D. Secci, M. Sterle, Š. Možina, Ž. Skok, N. Zidar, A. Zega, J. Ilaš, L. Peterlin Mašić, T. Tomašić, D. Hughes, D. L. Huseby, S. Cao, L. Garoff, T. Berruga Fernández, P. Giachou, L. Crone, I. Simoff, R. Svensson, B. Birnir, S. V. Korol, Z. Jin, F. Vicente, M. C. Ramos, M. de la Cruz, B. Glinghammar, L. Lenhammar, S. R. Henderson, J. E. A. Mundy, A. Maxwell, C. E. M. Stevenson, D. M. Lawson, G. V. Janssen, G. J. Sterk and D. Kikelj, *J. Med. Chem.*, 2023, **66**, 1380–1425.

37 M. Durcik, A. E. Cotman, Ž. Toplak, Š. Možina, Ž. Skok, P. E. Szili, M. Czikkely, E. Maharramov, T. H. Vu, M. V. Piras, N. Zidar, J. Ilaš, A. Zega, J. Trontelj, L. A. Pardo, D. Hughes, D. Huseby, T. Berruga-Fernández, S. Cao, I. Simoff, R. Svensson, S. V. Korol, Z. Jin, F. Vicente, M. C. Ramos, J. E. A. Mundy, A. Maxwell, C. E. M. Stevenson, D. M. Lawson, B. Glinghammar, E. Sjöström, M. Bohlin, J. Oreskär, S. Alvér, G. V. Janssen, G. J. Sterk, D. Kikelj, C. Pal, T. Tomašić and L. Peterlin Mašić, *J. Med. Chem.*, 2023, **66**, 3968–3994.

38 C. Ji and M. J. Miller, *Bioorg. Med. Chem.*, 2012, **20**, 3828–3836.

39 W. Neumann, M. Sassone-Corsi, M. Raffatellu and E. M. Nolan, *J. Am. Chem. Soc.*, 2018, **140**, 5193–5201.

40 C. Ji and M. J. Miller, *Biometals Int. J. Role Met. Ions Biol. Biochem. Med.*, 2015, **28**, 541–551.

41 M. E. Flanagan, S. J. Brickner, M. Lall, J. Casavant, L. Deschenes, S. M. Finegan, D. M. George, K. Granskog, J. R. Hardink, M. D. Huband, T. Hoang, L. Lamb, A. Marra, M. Mitton-Fry, J. P. Mueller, L. M. Mullins, M. C. Noe, J. P. O'Donnell, D. Pattavina, J. B. Penzien, B. P. Schuff, J. Sun, D. A. Whipple, J. Young and T. D. Gootz, *ACS Med. Chem. Lett.*, 2011, **2**, 385–390.

42 M. Durcik, Ž. Toplak, N. Zidar, J. Ilaš, A. Zega, D. Kikelj, L. P. Mašić and T. Tomašić, *ACS Omega*, 2020, **5**, 8305–8311.

43 S. J. Hearnshaw, T. T.-H. Chung, C. E. M. Stevenson, A. Maxwell and D. M. Lawson, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2015, **71**, 996–1005.

44 S. Bellon, J. D. Parsons, Y. Wei, K. Hayakawa, L. L. Swenson, P. S. Charifson, J. A. Lippke, R. Aldape and C. H. Gross, *Antimicrob. Agents Chemother.*, 2004, **48**, 1856–1864.

45 T. Baba, T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K. A. Datsenko, M. Tomita, B. L. Wanner and H. Mori, *Mol. Syst. Biol.*, 2006, **2**, 2006.

46 R. M. Humphries, J. Ambler, S. L. Mitchell, M. Castanheira, T. Dingle, J. A. Hindler, L. Koeth and K. Sei, *J. Clin. Microbiol.*, 2018, **56**, 019344.

47 J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. Skeel, L. Kalé and K. Schulten, *J. Comput. Chem.*, 2005, **26**, 1781–1802.

48 J. Huang, S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B. L. de Groot, H. Grubmüller and A. D. MacKerell, *Nat. Methods*, 2017, **14**, 71–73.

49 S. Jo, T. Kim, V. G. Iyer and W. Im, *J. Comput. Chem.*, 2008, **29**, 1859–1865.

50 J. Lee, X. Cheng, J. M. Swails, M. S. Yeom, P. K. Eastman, J. A. Lemkul, S. Wei, J. Buckner, J. C. Jeong, Y. Qi, S. Jo, V. S. Pande, D. A. Case, C. L. I. Brooks, A. D. MacKerell Jr, J. B. Klauda and W. Im, *J. Chem. Theory Comput.*, 2016, **12**, 405–413.

51 K. Vanommeslaeghe, E. Hatcher, C. Acharya, S. Kundu, S. Zhong, J. Shim, E. Darian, O. Guvench, P. Lopes,



I. Vorobyov and A. D. MacKerell Jr., *J. Comput. Chem.*, 2010, **31**, 671–690.

52 K. Vanommeslaeghe and A. D. MacKerell, *J. Chem. Inf. Model.*, 2012, **52**, 3144–3154.

53 K. Vanommeslaeghe, E. P. Raman and A. D. MacKerell Jr., *J. Chem. Inf. Model.*, 2012, **52**, 3155–3168.

54 U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee and L. G. Pedersen, *J. Chem. Phys.*, 1995, **103**, 8577–8593.

55 J.-P. Ryckaert, G. Ciccotti and H. J. C. Berendsen, *J. Comput. Phys.*, 1977, **23**, 327–341.

56 G. Wolber and T. Langer, *J. Chem. Inf. Model.*, 2005, **45**, 160–169.

